Skip to main content
Peter Campochiaro, MD, Ophthalmology, Baltimore, MD, Johns Hopkins Howard County Medical Center

PeterAnthonyCampochiaroMD

Ophthalmology • Baltimore, MD

Retinal Disease

Professor of Ophthalmology, Johns Hopkins University School of Medicine; George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience

Join to view full profile

Dr. Campochiaro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Campochiaro's full profile

Already have an account?

  • Office

    600 N. Wolfe Street
    Wilmer Eye Institute
    Baltimore, MD 21287
    Phone+1 410-955-3518
    Fax+1 410-614-7083
  • Is this information wrong?

Education & Training

  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Ophthalmology, 1979 - 1982
  • Johns Hopkins University
    Johns Hopkins UniversityInternship, Internal Medicine, 1978 - 1979
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1978
  • University of Notre Dame
    University of Notre DameB.S., Magna Cum Laude, 1970 - 1974

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1983 - 2024
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Achievement Award for Retinal Research Retinal Research Foundation and Retina Society, 2014
  • America's Top Doctors Castle Connolly, 2007-2014
  • Senior Research Achievement Award Macula Society, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Mechanism of Cone Cell Death in Retinitis Pigmentosa  
    Peter Campochiaro, MD, ScienceDirect
  • Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for retinal vein occlusion (ORVO) study  
    Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian, Am J Ophthalmol, 1/16/2015
  • Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes  
    Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Am J Ophthalmol, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Octreotide: The Next Decade 
    Chapter: Diabetic retinopathy: Current treatment and prospects for pharmacologic therapy 
    Campochiaro PAEditors: SWJ Lamberts.BioScientifica Ltd1999
  • Progress in Retinal and Eye Research 
    Chapter: Growth factors in the retina and retinal pigmented epithelium 
    Page 547 - 567Hackett SF and Vinores SAEditors: N.N. Osborne and G.J. Chader.Elsevier Science Ltd, England1996
  • Clinical Management of Poisoning and Drug Overdose 
    Chapter: Management of eye-related problems due to chemical and drug toxicity 
    Page 369 - 388Fogle JA and Spiker DAEditors: L.M. Haddad and J.F. Winchester.W.B. Saunders Co., PhiladelphiaEdition 2nd,1990
  • Join now to see all

Lectures

  • Mechanism of Cone Cell Death in Retinitis Pigmentosa 
    Lecce, Italy, 2010; Cordoba, Argentina, 2010; Schepens Eye Research Institute, 2015 - 1/1/2015
  • Mechanisms of Cone Cell Death in Retinitis Pigmentosa 
    Nagoya University, Nagoya, Japan - 1/1/2014
  • Treatment of Macular Edema Due to Retinal Vein Occlusions 
    Osaka, Japan - 1/1/2014
  • Join now to see all

Press Mentions

  • Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector
    Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS MicroinjectorFebruary 21st, 2023
  • 100, 100: Ending Diabetic Eye Disease, Forever
    100, 100: Ending Diabetic Eye Disease, ForeverMay 16th, 2022
  • REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
    REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference CallSeptember 27th, 2021
  • Join now to see all

Grant Support

  • New Treatments Of Ocular Neovascularization And Macular EdemaNational Eye Institute2012
  • Oxidative Damage And Cone Cell Death In RPNational Eye Institute2007–2012
  • The Role Of The Nicotinic Cholinergic Pathway In Retinopathy Of PrematurityNational Eye Institute2011
  • Targeting Survival Factors For Ocular NeovascularizationNational Eye Institute2007–2011
  • Molecular Signals Involved In Ocular NeovascularizationNational Eye Institute2002–2005
  • Function Of Pdgfs And Fgfs In The Retina And RPENational Eye Institute2000–2004
  • Retinal Neovascularization In Diabetic RetinopathyNational Eye Institute1999–2001
  • Functions Of Pdgfs And Fgfs In The Retina And RPENational Eye Institute1994–1999
  • Small Molecule Inhibitors Of Ocular NeovascularizationNational Eye Institute1998
  • Pathogenic Mechanisms In Proliferative VitreoretinopathyNational Eye Institute1990–1993
  • Pathogenic Mechanisms In Proliferative VitreoretinopathyNational Eye Institute1989–1990
  • Mechanisms In Retinal Pigment Epithelial Cell MigrationNational Eye Institute1985–1988

Hospital Affiliations

External Links

Dr. Peter Campochiaro, Dr. Peter Campochiaro, MD, Dr. P Campochiaro, Dr. Peter Anthony Campochiaro